Last reviewed · How we verify
lymphocytes immunophenotyping
At a glance
| Generic name | lymphocytes immunophenotyping |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)
- Impact of Thymectomy on Immunity in Infants After Cardiac Surgery (NA)
- Systemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation (NA)
- BD OneFlow CLPD Panel (BD OneFlow LST, and B-CLPD T1 to T4 Assays) on the BD FACSLyric System.
- Age-matched Reference Values for Circulating Natural Killer T-like Cells (NA)
- Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors (NA)
- Lymphocyte Immunophenotyping in Common Variable Immunodeficiency
- Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lymphocytes immunophenotyping CI brief — competitive landscape report
- lymphocytes immunophenotyping updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI